Summary

Global Markets Direct’s, ‘Vitiligo - Pipeline Review, H1 2016’, provides an overview of the Vitiligo pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vitiligo, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vitiligo and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vitiligo
- The report reviews pipeline therapeutics for Vitiligo by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Vitiligo therapeutics and enlists all their major and minor projects
- The report assesses Vitiligo therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Vitiligo

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Vitiligo
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Vitiligo pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents:

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Vitiligo Overview 6
Therapeutics Development 7
Pipeline Products for Vitiligo - Overview 7
Pipeline Products for Vitiligo - Comparative Analysis 8
Vitiligo - Therapeutics under Development by Companies 9
Vitiligo - Therapeutics under Investigation by Universities/Institutes 11
Vitiligo - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Vitiligo - Products under Development by Companies 14
Vitiligo - Products under Investigation by Universities/Institutes 15
Vitiligo - Companies Involved in Therapeutics Development 16
Ache Laboratorios Farmaceuticos S/A 16
Biocon Limited 17
Bristol-Myers Squibb Company 18
Clinuvel Pharmaceuticals Limited 19
Sun Pharma Advanced Research Company Ltd. 20
Vitiligo - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
abatacept - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ACH-24 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
afamelanotide - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Gene Therapy to Activate SOX9 for Vitiligo and Melanoma - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
itolizumab - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
SUN-0597 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
VLRX-001 - Drug Profile 43
Dec 03, 2015: Positive preliminary results in Singaporean vitiligo study
Dec 03, 2015: Update on North American vitiligo program for SCENESSE
May 05, 2015: Clinuvel announces innovative melanocortin for new indications
Mar 20, 2015: SCENESSE vitiligo data presented at world's largest dermatology conference
Sep 19, 2014: SCENESSE vitiligo study results published in JAMA Dermatology
May 06, 2014: Clinuvel's Phase II vitiligo study commences in Singapore
Mar 20, 2014: SCENESSE data to feature at American Academy of Dermatology
Nov 04, 2013: Clinuvel to start a Phase II vitiligo study in Singapore
Sep 02, 2013: Five month study follow up shows SCENESSE combination treatment provided stable repigmentation in vitiligo patients
Mar 01, 2013: SCENESSE data to be presented at American Academy of Dermatology, San Gallicano Rare Disease conference

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Vitiligo, H1 2016
Number of Products under Development for Vitiligo - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Investigation by Universities/Institutes, H1 2016
Vitiligo - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2016
Vitiligo - Pipeline by Biocon Limited, H1 2016
Vitiligo - Pipeline by Bristol-Myers Squibb Company, H1 2016
This person cannot share the publication (or any information contained therein) with any other person or persons.

Unless a Global License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.

Customers who infringe these license terms are liable for a Global license fee.

**Site License (PDF)**

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Global License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

**Global License (PDF)**

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.*

---

**Source URL:** https://www.marketresearchreports.com/global-markets-direct/vitiligo-pipeline-review-h1-2016

**Links**